BFM
MRSN

Boothbay Fund Management’s Mersana Therapeutics MRSN Stock Holding History

Boothbay Fund Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-892
Closed -$73.4K – 1952
2023
Q2 		$73.4K Buy
+892
New +$130K ﹤0.01% 1648
2021
Q2 		– Sell
-9
Closed -$362K – 2015
2021
Q1 		$362K Buy
+9
New +$4.37K 0.01% 1107

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boothbay Fund Management's MRSN Position: Q4 2023 in Review

Boothbay Fund Management sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 13,622 shares — an estimated $432K sold.

Boothbay Fund Management first reported a position in MRSN in Q1 2020 and held it in 6 quarters. The position peaked at $432K in Q3 2023. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Boothbay Fund Management reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 13,622 Mersana Therapeutics shares in Q4 2023, an estimated $432K.
  • Boothbay Fund Management first reported a position in Mersana Therapeutics in Q1 2020 and held it in 6 quarters.
  • Boothbay Fund Management's Mersana Therapeutics position peaked at $432K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.